| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target is the 5-HT3 receptor, a pentameric ligand-gated cation channel belonging to the Cys-loop superfamily. E-3620 behaves as a competitive antagonist at this receptor, blocking serotonin-evoked channel opening and thereby suppressing 5-HT3-mediated depolarization of vagal afferents, enteric neurons, and area postrema neurons. Its selectivity for 5-HT3 over other 5-HT receptor subtypes is a defining feature of the benzamide/tropane class, and this selectivity underlies its use as a pharmacological tool to dissect 5-HT3-dependent physiology without confounding activity at 5-HT1, 5-HT2, or 5-HT4 receptors.
|
|---|---|
| ln Vitro |
Functional in vitro potency is typically characterized in 5-HT3 receptor-expressing cell systems and in isolated tissue preparations rather than by a single published IC50 value. In radioligand binding assays using a 5-HT3-selective radioligand (e.g., [³H]granisetron or [³H]BRL-43694), E-3620 displaces specific binding in a concentration-dependent manner, yielding Ki values in the low nanomolar range typical of potent 5-HT3 antagonists. In functional assays, the compound right-shifts the serotonin concentration–response curve for 5-HT3-mediated cation influx (measured by fluorescent membrane-potential or Ca²⁺ dyes) or for 5-HT3-mediated contraction of isolated guinea-pig ileum, consistent with competitive antagonism.
|
| ln Vivo |
In vivo, E-3620 is effective in suppressing cisplatin-induced emesis in canine models, a classical 5-HT3-dependent readout. In beagle dogs, cisplatin triggers acute vomiting through 5-HT release from enterochromaffin cells and subsequent 5-HT3 activation on vagal afferents; E-3620 dose-dependently reduces or abolishes this emetic response, establishing in vivo target engagement. The compound is also used in animal models of dyskinesia and gastrointestinal motility disorders, where 5-HT3 blockade modulates enteric reflex activity and visceral sensory signaling.
|
| Enzyme Assay |
Non-cellular receptor-binding assays for E-3620 use membranes prepared from cells expressing recombinant 5-HT3A or native 5-HT3 receptors (e.g., N1E-115 neuroblastoma membranes or rat brainstem membranes). The membranes are incubated with a fixed concentration of a 5-HT3-selective radioligand and increasing concentrations of E-3620 in a physiological buffer; nonspecific binding is defined with an excess of a known 5-HT3 antagonist. After equilibrium, bound and free radioligand are separated by rapid filtration, and the retained radioactivity is counted to construct a displacement curve and calculate Ki.
|
| Cell Assay |
Cell-based functional assays use 5-HT3-expressing cell lines loaded with a fluorescent Ca²⁺ indicator or a membrane-potential dye. Cells are pre-incubated with E-3620 at graded concentrations, then stimulated with serotonin or a selective 5-HT3 agonist; the agonist-evoked Ca²⁺ transient or depolarization is recorded, and the rightward shift of the agonist concentration–response curve is used to calculate antagonist potency (pA2 or IC50). Isolated guinea-pig ileum longitudinal muscle–myenteric plexus preparations provide a complementary tissue-level assay: E-3620 is applied before cumulative serotonin concentrations, and the inhibition of 5-HT3-mediated contraction is quantified.
|
| Animal Protocol |
In vivo, beagle dogs receive E-3620 by an appropriate route (oral or intravenous) before cisplatin challenge, and the number and latency of emetic episodes are recorded over a defined observation period. Dose–response relationships are established by comparing emetic frequency in vehicle-treated versus E-3620-treated animals. For gastrointestinal motility studies, rodents or dogs receive the compound and transit is measured by charcoal meal progression or radiolabeled meal distribution; for dyskinesia models, drug-induced abnormal movements are scored after E-3620 pretreatment. Plasma exposure is measured in parallel to relate 5-HT3 occupancy to the functional endpoint.
|
| References |
| Molecular Formula |
C20H27CL2N3O2
|
|---|---|
| Molecular Weight |
412.353283166885
|
| Exact Mass |
411.148
|
| CAS # |
151213-86-4
|
| PubChem CID |
11281359
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
572
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC#C[C@H](C)OC1=CC(=C(C=C1C(=O)NC2C[C@H]3CC[C@@H](C2)N3C)Cl)N.Cl
|
| InChi Key |
GMHMNKHDLXRRGF-LZMJSSQSSA-N
|
| InChi Code |
InChI=1S/C20H26ClN3O2.ClH/c1-4-5-12(2)26-19-11-18(22)17(21)10-16(19)20(25)23-13-8-14-6-7-15(9-13)24(14)3;/h10-15H,6-9,22H2,1-3H3,(H,23,25);1H/t12-,13?,14-,15+;/m0./s1
|
| Chemical Name |
4-amino-5-chloro-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-[(2S)-pent-3-yn-2-yl]oxybenzamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~242.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4251 mL | 12.1256 mL | 24.2512 mL | |
| 5 mM | 0.4850 mL | 2.4251 mL | 4.8502 mL | |
| 10 mM | 0.2425 mL | 1.2126 mL | 2.4251 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
